NCT05845372
Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy
StatusRecruiting
PhaseNot specified
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 6 more changesShow less
- Eligibility criteria expanded, about 6 words
- Primary completion date changed from estimate of Jan 1, 2027 to Aug 1, 2026
- Study completion pushed from Jan 1, 2027 to May 1, 2027
- Secondary endpoints: details revised at 2 of 7 entries
- Site details revised at 19 of 19 sites
- Collaborators revised (19)
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
90-day mortality after onset
Timeframe: 90-day after onset
Incidence of stroke-associated pneumonia
Timeframe: within 7-day of onset
Secondary (7)
Incidence of clinically significant bleeding
Incidence of stress ulcer bleeding
Incidence of unfavorable functional prognosis at 90 days after onset
90-day mRS score change
Incidence of early neurological deterioration
Show 2 moreShow less
1-year post-onset mortality
Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset
Arms and interventions
Stress Ulcer Prophylaxis
Subjects are on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.
Control Group
Subjects are not on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.
Sites
19 sites in 1 country